BLLN — BillionToOne, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Diagnostics & Research·USA

Latest market price

98.00

+4.61+4.93%

Overview Short InterestFilings

BLLNQT46BillionToOne, Inc.·NASDAQ

Overview Short InterestFilings

98.00+4.93%

Loading chart...

Signal & projected range

Earnings big miss — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

VCYT-1.95%$46.30 SHC-0.77%$18.71 RDNT+8.09%$78.24 TWST+6.91%$123.66 NEOG-0.32%$11.43 CDNA+2.31%$47.77 QGEN+4.50%$44.20 PSNL+2.40%$14.50

Snapshot

Index	-	P/E	181.48	EPS (ttm)	0.51	Insider Own	-	Shs Outstand	46.00M	Perf Week	-32.62%

Market Cap	4.30B	Forward P/E	87.16	EPS next Y	1.07	Insider Trans	-	Shs Float	5.46M	Perf Month	-27.02%

Enterprise Value	3.90B	PEG	0.04	EPS next Q	0.07	Inst Own	-	Short Float	5.23%	Perf Quarter	0.53%

Income	25.34M	P/S	12.12	EPS this Y	213.11%	Inst Trans	-	Short Ratio	3.36	Perf Half Y	9.68%

Sales	354.54M	P/B	8.48	EPS next Y	26.30%	ROA	3.60%	Short Interest	2.41M	Perf YTD	14.11%

Book/sh	-	P/C	118.44	EPS next 5Y	16.82%	ROE	7.55%	52W High	157.85 -37.92%	Perf Year	-

Cash/sh	-	P/FCF	152.94	EPS past 3/5Y	-	ROIC	5.43%	52W Low	65.01 50.73%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	95.48	Sales past 3/5Y	-	Gross Margin	70.40%	Volatility	6.90% 6.03%	Perf 5Y	-

Dividend TTM	-	EV/Sales	11.01	EPS Y/Y TTM	19.35%	Oper. Margin	10.20%	ATR (14)	10.92	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	10.58	Sales Y/Y TTM	16.34%	Profit Margin	7.11%	RSI (14)	33.91	Recom	2.25

Dividend Gr. 3/5Y	-	Current Ratio	10.92	EPS Q/Q	209.09%	SMA20	-27.19%	Beta	1.77	Target Price	127.50

Payout	0.00%	Debt/Eq	0.29	Sales Q/Q	83.05%	SMA50	-19.44%	Rel Volume	1.91	Prev Close	93.39

Employees	713	LT Debt/Eq	0.21	Earnings	Oct 06	SMA200	-2.09%	Avg Volume	798.67K	Price	98.00

IPO Date	Nov 06, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	981.80% 11.59%	Net Debt/EBITDA	-9.62	Volume	1,524,085	Change	4.93%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-29-26	Reiterated	Guggenheim	Buy	$120 → $125
May-07-26	Reiterated	BTIG	Buy	$140 → $130
Mar-05-26	Reiterated	BTIG	Buy	$160 → $140
Jan-06-26	Initiated	Guggenheim	Buy	$120
Dec-01-25	Initiated	BTIG	Buy	$160
Dec-01-25	Initiated	Wells Fargo	Equal Weight	$110
Dec-01-25	Initiated	Stifel	Buy	$145
Dec-01-25	Reiterated	Piper Sandler		$150
Dec-01-25	Reiterated	Jefferies		$117

Latest News

Aug-05-26

Aug-05-2609:01PM

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com

09:00PM

Wondering what's happening in today's after-hours session?ChartMill

07:05PM

Billiontoone Q2 Earnings Call Highlightsmarketbeat.com

04:05PM

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidanceglobenewswire.com

Jul-29-26

Jul-29-2601:09PM

BillionToOne: The Guidance Looks Conservative, The Price Does NotSeekingAlpha

Jul-20-26

Jul-20-2609:00AM

BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstarprnewswire.com

Jul-15-26

Jul-15-2608:05AM

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026globenewswire.com

Jul-12-26

Jul-12-2607:56PM

A BillionToOne Insider Sold 801 Shares as Revenue Jumped 84%fool.com

Jul-08-26

Jul-08-2611:57AM

Tom Gardner's Five Stocks for the Long Term: Big Diversification, AI Research, and Cautionfool.com

Jul-02-26

Jul-02-2610:40AM

Are Medical Stocks Lagging BillionToOne, Inc. (BLLN) This Year?zacks.com

Jun-29-26

Jun-29-2601:00PM

BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Studygurufocus.com

Company

BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023
Total Revenue	178	305	153	—
Cost of Goods Sold Incl. D&A	76	97	72	—
Gross Profit	103	208	81	—
Selling, General and Administrative Excl. Other	100	143	91	—
Research and Development	40	49	37	—
Other Operating Expense	0	0	0	—
Operating Income	-39	16	-47	—
Interest Expense	1	0	2	—
Unusual Expense	—	—	—	—
Non-Operating Income (Expense)	5	-8	8	—
Net Income Before Taxes	-33	8	-42	—
Income Taxes	0	0	0	—
Consolidated Net Income	-33	7	-42	—
Net Income From Continuing Operations	-33	7	-42	—
Net Income	-33	7	-42	—
EPS (Recurring)	-0.75	0.06	-0.93	—
EPS (Basic, Before Extraordinaries)	-0.75	0.06	-0.93	—
EPS (Diluted)	-0.75	0.06	-0.93	—
EBITDA	-26	20	-27	—
Other After Tax Adjustments	—	—	—	—
Stock Option Compensation Expense	—	—	—	—
Price To Earnings Ratio	—	1,284.77	—	—
Price To Sales Ratio	24.77	12.34	—	—
Gross Margin	57.87	68.20	52.94	—
Operating Margin	-21.91	5.25	-30.72	—
Net Margin	-18.54	2.30	-27.45	—
Shares Outstanding	45	46	45	—
Market Capitalization	4,410	3,765	—	—
Operating Lease Expense	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.